Nisa Investment Advisors
DAWN

Nisa Investment Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Nisa Investment Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.02K Buy
234
+177
+311% +$2.49K ﹤0.01% 2454
2025
Q4 		$531 Sell
57
-1,000
-95% -$8.35K ﹤0.01% 2805
2025
Q3 		$7.45K Buy
1,057
+11
+1% +$76 ﹤0.01% 2360
2025
Q2 		$6.8K Buy
1,046
+46
+5% +$316 ﹤0.01% 2391
2025
Q1 		$7.93K Sell
1,000
-52
-5% -$560 ﹤0.01% 2156
2024
Q4 		$13.3K Sell
1,052
-42
-4% -$584 ﹤0.01% 2059
2024
Q3 		$15.2K Sell
1,094
-63
-5% -$899 ﹤0.01% 1992
2024
Q2 		$15.9K Buy
1,157
+1,063
+1,131% +$15.6K ﹤0.01% 2019
2024
Q1 		$1.55K Buy
94
+69
+276% +$1.03K ﹤0.01% 2281
2023
Q4 		$365 Sell
25
-762
-97% -$9.24K ﹤0.01% 2468
2023
Q3 		$9.66K Buy
787
+741
+1,611% +$9.67K ﹤0.01% 2183
2023
Q2 		$549 Buy
46
+16
+53% +$209 ﹤0.01% 2540
2023
Q1 		$0 Hold
30
– – ﹤0.01% 2566
2022
Q4 		$1K Buy
+30
New +$615 ﹤0.01% 2417

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Nisa Investment Advisors's DAWN Position: Q1 2026 in Review

Nisa Investment Advisors increased its Day One Biopharmaceuticals (DAWN) stake by 311% in Q1 2026, buying an estimated $2.49K and bringing the position to 234 shares worth $5.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

Nisa Investment Advisors first reported a position in DAWN in Q4 2022 and has held it in 14 quarters since. The position peaked at $15.9K in Q2 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Nisa Investment Advisors held 234 shares of Day One Biopharmaceuticals worth $5.02K as of Q1 2026.
  • Nisa Investment Advisors bought 177 Day One Biopharmaceuticals shares in Q1 2026, an estimated $2.49K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2454 holding.
  • Nisa Investment Advisors first reported a position in Day One Biopharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Nisa Investment Advisors's Day One Biopharmaceuticals position peaked at $15.9K in Q2 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.